13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05378100
(ClinicalTrials.gov)		January 1, 202312/5/2022Ketamine for Multiple Sclerosis FatigueLow-Dose Ketamine Infusion for the Treatment of Multiple Sclerosis Fatigue (INKLING-MS)Multiple Sclerosis FatigueDrug: Ketamine;Drug: MidazolamJohns Hopkins UniversityUnited States Department of DefenseRecruiting18 Years65 YearsAll110Phase 2United States
2NCT03500289
(ClinicalTrials.gov)		August 10, 20184/4/2018Ketamine for Treatment of MS FatigueKetamine for Treatment of Multiple Sclerosis-related FatigueMultiple Sclerosis;FatigueDrug: Ketamine;Drug: MidazolamJohns Hopkins UniversityNational Multiple Sclerosis SocietyCompleted18 Years65 YearsAll18Phase 1/Phase 2United States